Prana Thoracic, a startup focused on earlier detection and intervention for lung cancer, recently won the medical devices track of the MedCity News INVEST Pitch Perfect contest. The company is developing a minimally invasive electrosurgical device to help thoracic surgeons better excise smaller and intermediate-size lung nodules.
In an interview, the deputy director and chief innovation officer of Translational Research Institute for Space Health, headquartered at Baylor College of Medicine, described some of the group's work, adapting known tech for space applications and using space-based insights to improve healthcare at home.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The findings may make it possible to identify a subset of patients who experience poorer outcomes or more serious side effects, especially neurotoxicity.
Data from 11 patients in an MD Anderson study of a cell therapy that uses natural killer (NK) cells from donors instead of patients' own T cells showed a high response rate and low toxicity. A multicenter, international Phase II study is planned.
The Senate voted 72-18 Thursday to confirm Hahn, a radiation oncologist and chief medical executive at The University of Texas MD Anderson Cancer Center.
HHS announced that it had nominated Dr. Stephen Hahn as the next FDA commissioner. Acting Commissioner Ned Sharpless will return to the National Cancer Institute, while HHS official Brett Giroir will temporarily step in pending Hahn's confirmation.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Dr. Stephen Hahn, a radiation oncologist and MD Anderson's chief medical executive, has reportedly been in the running since September to succeed former FDA Commissioner Scott Gottlieb and current acting commissioner Ned Sharpless.
BioCentury reported that the the nomination of radiation oncologist Dr. Stephen Hahn, who had been under consideration, would follow an FBI background check. Acting Commissioner Ned Sharpless and Brett Giroir, an assistant HHS secretary, had also reportedly been in the running.
Trump is reportedly considering Dr. Stephen Hahn to head the FDA. Others reportedly under consideration include acting Commissioner Ned Sharpless and HHS assistant secretary Brett Giroir.
Juliana Garaizar's removal marks the second time in the past 12 months that TMC's leadership is making executive changes at the very top of organizations under its umbrella that are dedicated to startup investing and innovation.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
Oscar, which was initially founded in 2012 to serve the emerging Obamacare insurance exchanges, decided to enter into Medicare Advantage after a $375 million funding round from Alphabet last year.
The Houston-based company is developing a cell therapy for viral infections in patients with compromised immune systems, which it plans to move into Phase III studies within the next 12 months. AlloVir also raised $120 million in a Series B funding round.
Houston-based CorInnova won the medical device track for the Pitch Perfect contest at the MedCity INVEST conference in Chicago.
In partnership with clinic operator VillageMD, Walgreens plans to open five 2,500-square-foot in-store clinics in the Houston area by the end of the year.